Latest market price
420.07
-1.95-0.46%
OverviewShort InterestFilings
ELVQT73Elevance Health Inc.·NYSE
420.07-0.46%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CI-0.06%$298.23CVS-0.09%$90.25HUM-0.73%$414.50CNC-0.25%$68.45UNH-0.96%$406.97MOH+2.93%$204.78OSCR-1.36%$30.37CLOV-2.62%$4.46
Snapshot
IndexS&P 500P/E17.91EPS (ttm)23.45Insider Own0.35%Shs Outstand216.87MPerf Week-4.52%
Market Cap91.10BForward P/E13.89EPS next Y30.25Insider Trans-1.19%Shs Float215.57MPerf Month10.06%
Enterprise Value84.01BPEG1.44EPS next Q2.17Short Float2.38%Perf Quarter9.74%
Income5.14BP/S0.45EPS this Y-3.13%Short Ratio4.53Perf Half Y12.72%
Sales201.83BP/B2.03EPS next Y4.12%ROA4.02%Short Interest5.14MPerf YTD19.83%
Book/sh206.55P/C2.41EPS next 5Y12.41%ROE11.59%52W High450.69 -6.79%Perf Year24.89%
Cash/sh174.51P/FCF13.99EPS past 3/5Y1.14% 6.92%ROIC7.47%52W Low274.84 52.84%Perf 3Y-6.67%
Dividend Est.6.88 (1.64%)EV/EBITDA9.46Sales past 3/5Y8.34% 10.32%Gross Margin36.55%Volatility2.65% 2.72%Perf 5Y-3.06%
Dividend TTM6.87 (1.64%)EV/Sales0.42EPS Y/Y TTM-4.13%Oper. Margin3.69%ATR (14)11.55Perf 10Y238.68%
Dividend Ex-DateDec 04, 2026Quick Ratio1.47Sales Y/Y TTM3.60%Profit Margin2.55%RSI (14)50.77Recom2.29
Dividend Gr. 3/5Y10.14% 12.47%Current Ratio1.47EPS Q/Q15.92%SMA20-0.50%Beta0.63Target Price466.69
Payout29.17%Debt/Eq0.69Sales Q/Q1.42%SMA502.32%Rel Volume1.10Prev Close422.02
Employees96,615LT Debt/Eq0.68EarningsJan 27SMA20012.81%Avg Volume1.16MPrice420.07
IPO DateOct 30, 2001Option/ShortYes / YesEPS/Sales Surpr.48.28% 2.35%Net Debt/EBITDA-0.80Volume1,286,073Change-0.46%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-23-26ReiteratedPiper Sandler$409 → $520
Oct-23-26ReiteratedMizuho SecuritiesOutperform$470 → $490
Oct-23-26ReiteratedGoldman SachsBuy$395 → $451
Oct-22-26ReiteratedRobert W. Baird$393 → $406
Oct-22-26ReiteratedGuggenheimBuy$460 → $485
Oct-22-26ReiteratedRBC CapitalSector Perform$424 → $455
Oct-22-26ReiteratedBarclaysOverweight$469 → $472
Oct-22-26ReiteratedUBSBuy$460 → $523
Oct-12-26ReiteratedGuggenheimBuy$455 → $460
Oct-07-26ReiteratedBarclaysOverweight$457 → $469
Latest News· Times ET
Oct-30-26
Oct-30-2601:01PM
Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Knowzacks.com
Oct-28-26
Oct-28-2604:52PM
AxoGen, Inc. Q3 2026 Earnings Call SummaryYahoo
Oct-27-26
Oct-27-2607:22AM
ELV Fairly Valued by DCF at $418gurufocus.com
04:20AM
Elevance Health, Inc. $ELV Stock Acquired by Citizens Financial Group Inc. RIdefenseworld.net
Oct-26-26
Oct-26-2610:01AM
Implied Volatility Surging for Elevance Health Stock Optionszacks.com
Oct-25-26
Oct-25-2605:16AM
Elevance Health, Inc. $ELV Stock Sold by Iridian Asset Management LLC CTdefenseworld.net
04:38AM
Elevance Health (NYSE:ELV) Stock: Insider Mark Kaye Sells 10,584 Sharesdefenseworld.net
Oct-23-26
Oct-23-2612:40PM
ELV vs. RVTY: Which Stock Is the Better Value Option?zacks.com
Oct-21-26
Oct-21-2611:58PM
Elevance Health: Better Results, But Not Enough To Buyseekingalpha.com
11:49PM
Elevance: 3 Key Takeaways for Long-Term Investorsfool.com
06:51PM
2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRGzacks.com
04:46PM
Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run?zacks.com
01:17PM
Elevance (ELV) Q3 2026 Earnings Call TranscriptYahoo
12:24PM
Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcriptseekingalpha.com
12:21PM
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlookzacks.com
Company

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue201,831199,125176,810171,340—————
Cost of Goods Sold Incl. D&A128,054148,223127,567124,330—————
Gross Profit73,77750,90249,24347,010—————
Selling, General and Administrative Excl. Other
12,082000—————
Research and Development
0000—————
Other Operating Expense54,23842,79040,35538,265—————
Operating Income7,4578,1128,8888,745—————
Interest Expense1,1371,4021,1851,030—————
Unusual Expense
—————————
Non-Operating Income (Expense)-7002010—————
Net Income Before Taxes6,2506,7107,9047,715—————
Income Taxes1,1471,0491,9331,724—————
Consolidated Net Income5,1395,6625,9805,987—————
Net Income From Continuing Operations5,1035,6615,9715,991—————
Net Income5,1395,6625,9805,987—————
EPS (Recurring)23.4825.1825.8125.38—————
EPS (Basic, Before Extraordinaries)23.4825.1825.8125.38—————
EPS (Diluted)23.4525.1225.6825.22—————
EBITDA8,8769,65810,48210,490—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio17.9113.9614.3718.70—————
Price To Sales Ratio0.450.390.490.64—————
Gross Margin36.5525.5627.8527.44—————
Operating Margin3.694.075.035.10—————
Net Margin2.552.843.383.49—————
Shares Outstanding218222233233—————
Market Capitalization91,57577,82285,954109,873—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$469.96$416.49$363.01$309.53$256.06● Close Price0.00M1.16M2.33M3.49M4.66MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kaye MarkEVP & CFOOct 22 '26Sale440.1310,5844,658,35719,919Oct 23
PERU RAMIRO GDirectorJul 17 '26Buy366.051,000366,05010,908Jul 17
BOUDREAUX GAILPresident and CEOJul 17 '26Buy367.792,7251,002,230171,976Jul 17
Penczek Ronald WCAO & ControllerJun 12 '26Sale403.16369148,7663,740Jun 15
Dixon Robert L JRDirectorJun 11 '26Sale401.7715160,66710,734Jun 12
Penczek Ronald WCAO & ControllerMay 19 '26Sale403.131,531617,1924,109May 20
Penczek Ronald WCAO & ControllerMay 19 '26Option Exercise294.301,531450,5795,640May 20
SCHULMAN AMY WDirectorMar 12 '26Sale287.50267,475218Mar 23
Kendrick Charles Morgan JREVP & President, CommercialMar 06 '26Sale284.923,196910,60411,791Mar 09
COLLIS STEVEN HDirectorMar 05 '26Buy289.843,000869,5203,639Mar 06
DeVore Susan D.DirectorAug 19 '25Buy312.151,200374,5803,502Aug 21
BOUDREAUX GAILPresident and CEOJul 18 '25Buy286.948,5002,438,951151,020Jul 18
Kaye MarkEVP & CFOApr 24 '25Sale424.824,5881,949,07418,977Apr 25
Penczek Ronald WCAO & ControllerMar 10 '25Sale415.13443183,9031,847Mar 11
Kendrick Charles Morgan JREVP & President, CommercialMar 05 '25Sale396.303,5041,388,63510,116Mar 05
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.